May 8, 2024, 4:41 a.m. | Bing Hu, Ashish Saragadam, Anita Layton, Helen Chen

cs.LG updates on arXiv.org arxiv.org

arXiv:2405.03799v1 Announce Type: new
Abstract: Artificial intelligence (AI) is increasingly used in every stage of drug development. Continuing breakthroughs in AI-based methods for drug discovery require the creation, improvement, and refinement of drug discovery data. We posit a new data challenge that slows the advancement of drug discovery AI: datasets are often collected independently from each other, often with little overlap, creating data sparsity. Data sparsity makes data curation difficult for researchers looking to answer key research questions requiring values …

abstract advancement artificial artificial intelligence arxiv challenge cs.ai cs.lg data datasets development diffusion diffusion models discovery drug development drug discovery every improvement intelligence posit prediction q-bio.qm stage synthetic synthetic data type

Software Engineer for AI Training Data (School Specific)

@ G2i Inc | Remote

Software Engineer for AI Training Data (Python)

@ G2i Inc | Remote

Software Engineer for AI Training Data (Tier 2)

@ G2i Inc | Remote

Data Engineer

@ Lemon.io | Remote: Europe, LATAM, Canada, UK, Asia, Oceania

Artificial Intelligence – Bioinformatic Expert

@ University of Texas Medical Branch | Galveston, TX

Lead Developer (AI)

@ Cere Network | San Francisco, US